Compugen

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Compugen reports Q1 loss, showcases promising cancer immunotherapy approach

Compugen's Q1 2023 performance reflects a strategic focus on capital efficiency and milestone achievement.
Their innovative triple combination approach in cancer immunotherapy shows promise, with encouraging clinical benefits observed.
While managing R&D expenses and translating clinical benefits into marketable products are challenges, opportunities exist in disciplined cash deployment and exploration of biomarkers.
Overall, Compugen's financial discipline, promising clinical data, and strategic focus position them well for future growth in the oncology space.

Compugen (CGEN) reports positive ASCO results and solid financial standing

Compugen (CGEN) showcases promising results in cancer immunotherapy combinations, maintaining a strong financial position despite increased R&D expenses. The company's differentiated approach and focus on milestone achievement through 2024 position it well for future growth, although challenges in enrollment delays and managing expenses persist.

Compugen reports Q3 progress with promising clinical data and partnerships

Compugen's Q3 2023 performance reflects progress in clinical trials and financial stability with a cash balance of $57.5 million.
Strengths lie in innovative drug discovery approaches, successful clinical outcomes, and strategic partnerships.
Challenges include competitive enrollment landscape, cost management, and market acceptance of novel treatments.
Opportunities exist in upcoming data reporting, novel drug targets, and collaborations for future growth and success.

Compugen reports robust earnings and strategic partnerships drive growth

Compugen's Q4 2023 performance reflects strong financial results and notable achievements in clinical advancements and partnerships.
The company's financial stability, strategic focus, and robust pipeline position them well for future growth and innovation.
While facing challenges in clinical trial outcomes and partnership strategies, Compugen has opportunities to drive further growth through data insights and collaborations.

Compugen reports solid Q1 performance, poised for growth in 2024

Compugen's Q1 2024 performance reflects financial stability, operational efficiency, and progress in advancing key drug candidates towards clinical trials, underpinned by a robust AI discovery platform and strategic partnerships.
While challenges like ongoing R&D investments and achieving profitability persist, opportunities in milestone achievements, data readouts, and strategic collaborations position Compugen for future growth and value creation.
Navigating the biopharmaceutical landscape with innovation, financial discipline, and strategic foresight, Compugen stands poised to capitalize on market opportunities, drive pipeline progression, and enhance shareholder value.

Compugen reports Q2 revenue of $6.7M, highlights innovative drug strategies

Compugen's Q2 2024 performance reflects steady revenue generation and prudent financial management. The company's strengths in innovative drug development and strategic collaborations present promising growth opportunities. Addressing challenges in clinical evidence and cash burn will be crucial for sustained success.

Compugen reports solid Q3 earnings, advances promising ovarian cancer therapies

Compugen's strong financial position, promising clinical data on multiple therapies, and strategic focus on ovarian cancer treatment advancements position the company for potential growth. Challenges lie in maintaining treatment efficacy and navigating regulatory discussions for future developments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOLON, ISRAEL , May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2024 financial results on Monday, May 20, 2024, before the U.S. financial markets open.

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

HOLON, Israel , April 25, 2024 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May31-June 4 2023, in Chicago, Illinois.

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the simultaneous online publication of a peer reviewed paper titled 'Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects' link, in Cancer Immunology Research, a journal of the American Association for Cancer Research with a presentation at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

HOLON, Israel , April 3, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming investor conferences in April: 23rd Annual Needham Virtual Healthcare Conference Date: Wednesday, April 10, 2024, at 8:00 AM ET Location: Virtual Format: Presentation Canaccord Genuity Horizons in Oncology Virtual Conference Date: Monday, April 15, 2024, at 9:00 AM ET Location: Virtual Format: Panel: Novel Immune Checkpoints - There's more than one way to stimulate a T-cell Live webcast of the presentation and a replay will be available on the Investor Relations section of Compugen's website at www.cgen.com.

Compugen to Participate in Two Upcoming Investor Conferences

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice

HOLON, Israel , March 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has been selected to give two oral presentations at the Keystone Symposium on Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance, taking place March 17-21, 2024, in Whistler, Canada.

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

HOLON, Israel , March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

Compugen Ltd. (NASDAQ:CGEN ) Q4 2023 Earnings Conference Call March 5, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Eran Ophir - Chief Scientific Officer Michelle Mahler - Chief Medical Officer Conference Call Participants Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Stephen Willey - Stifel Operator Ladies and gentlemen, thank you for joining us today.

Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript

Partnership with Gilead on preclinical immuno-oncology program further validates Compugen's computational discovery, research, and development capabilities Catalyst rich 2024 expected with multiple data readouts and updates planned from Compugen's diversified portfolio Solid balance sheet with extended cash runway expected to fund operations into 2027 HOLON, Israel , March 5, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today reported financial results for the fourth quarter and full year 2023 and provided a corporate update.

Compugen Reports Fourth Quarter and Full Year 2023 Results

Compugen (CGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Compugen (CGEN) This Earnings Season?

HOLON, Israel , Feb. 26, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, on Monday, March 11, 2024 at 11:20 AM ET.

Compugen to Present at the Leerink Partners Global Biopharma Conference 2024

Compugen (CGEN) is a Great Momentum Stock: Should You Buy?

HOLON, Israel , Feb. 20. 2024 /PRNewswire/ -- Compugen Ltd.

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

HOLON, Israel , Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D.

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

Canaan Inc.

Ceragon Networks

Dyne Therapeutics

Rocket Pharma

The RealReal

Xperi

While investors should probably direct the majority of their market-earmarked funds toward slow-and-steady ideas – à la Warren Buffett – sometimes, we end up with gambling money. And in that case, speculative stocks to double your money might make sense.

7 Speculative Stocks to Double Your Money THIS Year

Agenus

Bristol-Myers

GlaxoSmithKline

iTeos Therapeutics, Inc.

Merck

Novartis

Pfizer

Arcus Biosciences

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

AstraZeneca

HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on January 4, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD) announced that it has entered into an agreement with Compugen Ltd (NASDAQ:CGEN) to exclusively license Compugen's pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate, which is targeting cancer.   Per the agreement, Compugen will be responsible for the ongoing pre-clinical development and future Phase 1 study of COM503 after which Gilead will have the sole right to develop and commercialize the drug.

Gilead Sciences and Compugen strike commercialization deal for immunotherapy program

Compugen (NASDAQ: CGEN ) stock is rocketing higher on Tuesday after announcing an exclusive licensing agreement with Gilead Sciences (NASDAQ: GILD ). According to a press release from Compugen, this agreement covers its anti-IL-18 binding protein program.

Why Is Compugen (CGEN) Stock Up 189% Today?

Compugen Ltd.'s stock CGEN, -3.36% was up by 113% in premarket trading on Tuesday after the company said it agreed to sell exclusive rights to Gilead Sciences Inc. GILD, -1.03% for later stage development and commercialization of Anti-IL 18 binding protein antibodies with potential to treat various types of tumors.

Compugen stock rockets on anti-tumor drug deal with Gilead

Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca (LSE/STO/Nasdaq: AZN), when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreement HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will host a conference call at 8:30 AM ET today, to discuss the exclusive license agreement with Gilead announced today, for the development and commercialization of its anti-IL-18 binding protein program including COM503, a pre-clinical potential first-in-class high affinity antibody targeting IL-18 binding protein with potential to treat multiple tumor types.

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

FOSTER CITY, Calif. & HOLON, Israel--(BUSINESS WIRE)--Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program.

News for Compugen Stock (CGEN)